The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.

Resources

Discussion paper on pan-tumour biomarker testing to determine eligibility for targeted treatment

This paper provides guidance on the evidence needed to evaluate immunohistochemistry (IHC) testing for mismatch repair deficiency (dMMR) in colorectal cancer and many other types of tumours, to access pembrolizumab treatment.

Scroll down to access downloads and media.

Download PDF - 690.93 KB

Download Word - 304.67 KB

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Publication type:

Report

Date of official publication:

January 2020

Language:

English

Part of a collection:

Integrated codependent submissions for tumour-agnostic or pan-tumour cancer medicines

Last updated:

17 October 2024

Tags:

MSAC support

Sub menu

Discussion paper on pan-tumour biomarker testing to determine eligibility for targeted treatment

Help us improve